FDA Inspection 1266345 — Synexa Life Sciences
The FDA completed an inspection of Synexa Life Sciences on Sep 6, 2024 in Cape Town. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Sep 6, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cape Town (South Africa)
Additional Details
Bioanalytical BA/BE